May 23, 2007

Vanda Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central  nervous system disorders, has announced the initiation of a Phase II clinical trial of its product candidate VSF-173 in excessive sleepiness.

The trial is a randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of three oral doses of VSF-173 for the treatment of induced excessive sleepiness in approximately 60 healthy male and female subjects. The primary endpoint of the study is the difference from placebo on the maintenance of wakefulness test, a standard measure of sleepiness.